A5083566276- Transgenic Plants and Applications
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Plant tissue culture and regeneration
- Pharmaceutical and Antibiotic Environmental Impacts
- Vaccine Coverage and Hesitancy
- Viral Infectious Diseases and Gene Expression in Insects
- Viral Infections and Immunology Research
- Animal Virus Infections Studies
- Plant Virus Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Antibiotic Resistance in Bacteria
- Toxin Mechanisms and Immunotoxins
- CRISPR and Genetic Engineering
- Environmental Toxicology and Ecotoxicology
- COVID-19 Impact on Reproduction
- Pineapple and bromelain studies
- Aquaculture Nutrition and Growth
- Diabetes and associated disorders
- Grief, Bereavement, and Mental Health
- Phytase and its Applications
- Reproductive System and Pregnancy
- Death Anxiety and Social Exclusion
- Nanoparticles: synthesis and applications
Medicago (Canada)
2010-2023
McGill University
2023
Université du Québec à Montréal
2021
Environment and Climate Change Canada
2011-2016
Hertfordshire Community NHS Trust
2008
Université Laval
1997-1999
The recent swine H1N1 influenza outbreak demonstrated that egg-based vaccine manufacturing has an Achille's heel: its inability to provide a large number of doses quickly. Using novel platform based on transient expression surface glycoproteins in Nicotiana benthamiana, we have recently candidate Virus-Like Particle (VLP) can be generated within 3 weeks release sequence information. Herein report alum-adjuvanted plant-made VLPs containing the hemagglutinin (HA) protein H5N1...
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ). The co-primary outcomes...
Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of original strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) combined with an adjuvant (Adjuvant System 03 [AS03]) to form candidate vaccine.In this phase 3, multinational, randomized, placebo-controlled trial conducted at 85 centers, we assigned adults (≥18 years age) a 1:1 ratio receive two intramuscular injections CoVLP+AS03 vaccine or placebo 21 days apart. The...
Summary A strain‐specific vaccine represents the best possible response to threat of an influenza pandemic. Rapid delivery such a world's population before peak first infection wave seems be unattainable goal with current manufacturing capacity. Plant‐based transient expression is one few production systems that can meet anticipated surge requirement. To assess capability plant agroinfiltration produce vaccine, we expressed haemagglutinin (HA) from strains A/Indonesia/5/05 (H5N1) and A/New...
Recent issues regarding efficacy of influenza vaccines have re-emphasized the need new approaches to face this major public health issue. In a phase 1-2 clinical trial, healthy adults received one intramuscular dose seasonal plant-based quadrivalent virus-like particle (QVLP) vaccine or placebo. The hemagglutination inhibition (HI) titers met all European licensure criteria for type A strains at 3μg/strain and four higher dosages 21days after immunization. High HI were maintained most...
Background New influenza vaccines eliciting more effective protection are needed, particularly for the elderly who paid a large and disproportional toll of hospitalization dead during seasonal epidemics. Low (≤15 μg/strain) doses new plant-derived virus-like-particle (VLP) vaccine candidate have been shown to induce humoral cellular responses against both homologous heterologous strains in healthy adults 18–64 years age. The two clinical trials reported here addressed safety immunogenicity...
Abstract Although antivirals are important tools to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, effective vaccines essential the current disease 2019 (COVID-19) pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here, we report protection induced in rhesus macaques by intramuscular injections of a VLP bearing SARS-CoV-2 spike protein (CoVLP) candidate formulated...
The hemagglutinination inhibition (HI) response remains the gold standard used for licensure of influenza vaccines. However, cell-mediated immunity (CMI) deserves more attention, especially when evaluating H5N1 vaccines that tend to induce poor HI response. In this study, we measured humoral and CMI (flow cytometry) during a Phase II dose-ranging clinical trial (NCT01991561). Subjects received two intramuscular doses, 21 days apart, plant-derived virus-like particles (VLP) presenting...
Longer Abstract Background The stabilized prefusion form of the SARS-CoV-2 spike protein is produced by transient expression in Nicotiana benthamiana . trimeric glycoproteins are displayed at surface self-assembling Virus-Like-Particles that mimic shape and size virus. candidate vaccine (CoVLP) administered alone or with AS03 CpG1018 adjuvants was evaluated a Phase 1 trial healthy adults. ( ClinicalTrials.gov number NCT04450004 ) Methods study randomized, partially-blinded, prime-boost 21...
Abstract The rapid spread of SARS-CoV-2 continues to impact humanity on a global scale with rising total morbidity and mortality. Despite the development several effective vaccines, new products are needed supply ongoing demand needs specific populations. We report herein pre-specified interim analysis phase 2 portion an Phase 2/3, randomized, placebo-controlled trial coronavirus virus-like particle (CoVLP) vaccine candidate produced in plants that displays spike glycoprotein adjuvanted AS03...
The rapid spread of SARS-CoV-2 continues to impact humanity on a global scale with rising total morbidity and mortality. Despite the development several effective vaccines, new products are needed supply ongoing demand fight variants. We report herein pre-specified interim analysis phase 2 portion Phase 2/3, randomized, placebo-controlled trial coronavirus virus-like particle (CoVLP) vaccine candidate, produced in plants that displays spike glycoprotein, adjuvanted AS03 (NCT04636697). A 753...
Summary Structural analysis of the N‐glycosylation alfalfa proteins was investigated in order to evaluate capacity this plant perform biologically important post‐translational modification. We show that, alfalfa, N‐linked glycans are processed into a large variety mature oligosaccharides having core‐xylose and core α(1,3)‐fucose, as well terminal Lewis epitopes. In contrast, expression C5‐1 monoclonal antibody plants results production plant‐derived IgG 1 which is N‐glycosylated by...
Summary Proteolytic degradation represents a significant barrier to the efficient production of several recombinant proteins in plants, both vivo during their expression and vitro recovery from source tissues. Here, we describe strategy protect process, based on coexpression heterologous proteinase inhibitor acting as ‘mouse trap’ against host proteases extraction. After confirming importance trypsin‐ chymotrypsin‐like activities crude protein extracts potato ( Solanum tuberosum L.) leaves,...
Burkholderia cepacia is recognized as an important pathogen in the lung infections of patients with cystic fibrosis. An inducible beta-lactamase activity has been associated increased resistance to beta-lactam antibiotics clinical isolates B. cepacia. In this study, we report revised sequence penA gene, which encodes penicillinase cepacia, and show that it belongs molecular class A beta-lactamases exhibits a high degree similarity chromosomal Klebsiella oxytoca. Analysis nucleotide DNA...